| Uses and limitations of portal vein embolization for improving perioperative outcomes in hepatocellular carcinoma. | |
| | |
MedLine Citation:
|
PMID: 20494702 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Hepatic resection remains the only curative option for the majority of patients with hepatocellular carcinoma (HCC) who do not meet criteria for transplantation or local ablative options. As the majority of patients with HCC also have underlying chronic liver disease and cirrhosis, post-hepatectomy complications can be significant, and in some prohibitive. The technique of portal vein embolization (PVE) has evolved to increase the candidacy of patients for major hepatectomy, as well as improve postoperative outcomes and safety. This review will focus on PVE and discuss our institution's experience with uses and limitations of this technique for HCC. |
| | |
Authors:
|
Mark J Truty; Jean-Nicolas Vauthey |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Seminars in oncology Volume: 37 ISSN: 1532-8708 ISO Abbreviation: Semin. Oncol. Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-05-24 Completed Date: 2010-06-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0420432 Medline TA: Semin Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 102-9 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carcinoma, Hepatocellular
/
therapy* Embolization, Therapeutic / methods* Hepatectomy Humans Liver Neoplasms / therapy* Portal Vein / surgery* Treatment Outcome |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Yttrium-90 Radioembolization in the Management of Liver Malignancies.
Next Document: Locoregional Intra-arterial Therapies for Unresectable Intrahepatic Cholangiocarcinoma.